News
Important Only
Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter And Full Year 2025 Revenue Results
Jan 12 (Reuters) - Apyx Medical Corp APYX.O:ORATION REPORTS PRELIMINARY, UNAUDITED, FOURTH QUARTER AND FULL YEAR 2025 REVENUE RESULTSQ4 REVENUE EXPECTED BETWEEN $19.0-$19.2 MILLION, UP 34% YOYQ4 REVENUE VIEW $17.4 MILLION -- LSEG IBES DATAFurther company coverage: APYX.OReuters
Mon, Jan 12
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs
Jan 12 (Reuters) - Moleculin Biotech Inc MBRX.O:MOLECULIN ACCELERATES OUTLOOK INTO 2026 WITH FIRST PIVOTAL TRIAL UNBLINDING ON TRACK, GLOBAL TRIAL EXPANSION, AND MULTIPLE EXTERNALLY/IIT FUNDED CLINICAL PROGRAMSMOLECULIN BIOTECH INC - FIRST MIRACLE TRIAL UNBLINDING EXPECTED Q1 2026; GLOBAL TRIAL NOW ...Reuters
Mon, Jan 12
Oxygen concentrator maker Inogen's prelim Q4 revenue grows 2% on strong B2B performance
OverviewMedical technology firm's preliminary Q4 revenue grew 2% Company expects positive Adjusted EBITDA for full yr 2025OutlookCompany to provide 2026 financial guidance during February earnings callResult DriversORDER TIMING SHIFT - Q4 revenue impacted by delay in large customer orders to 202...Reuters
Mon, Jan 12
IceCure Medical's prelim 2025 revenue misses expectations
OverviewIsrael cryoablation firm's preliminary 2025 revenue missed analyst expectationsCompany experienced strong U.S. demand following FDA authorization for ProSenseRecord European sales driven by U.S. clearance and growing ProSense adoptionOutlookIceCure expects higher ProSense® sales in 2026 ...Reuters
Mon, Jan 12
Alliance Entertainment Holding Corp - Agreement Includes James Bond And Rocky Franchises
Jan 12 (Reuters) - Alliance Entertainment Holding Corp AENT.O:ALLIANCE ENTERTAINMENT HOLDING CORP - AGREEMENT INCLUDES JAMES BOND AND ROCKY FRANCHISESALLIANCE ENTERTAINMENT NAMED EXCLUSIVE PHYSICAL MEDIA DISTRIBUTION PARTNER FOR AMAZON MGM STUDIOS IN NORTH AMERICAReuters
Mon, Jan 12
ClearPoint Neuro prelim Q4 revenue rises
OverviewDevice and therapy firm's preliminary Q4 revenue rose 20% yr/yr to $10.4 mlnCompany expects 2026 revenue between $54 mln and $60 mlnPreliminary results show growth in neurosurgery disposables and biologics deliveryOutlookClearPoint Neuro expects 2026 revenue between $54 mln and $60 mlnCo...Reuters
Mon, Jan 12
Volkswagen's fourth-quarter deliveries decline as Chinese, US demand softens
By Amir Orusov Jan 12 (Reuters) - German carmaker Volkswagen VOWG_p.DE saw a 4.9% decline in vehicle deliveries in the fourth quarter of 2025, driven by lower demand in North America and China, the company said on Monday.The company delivered 2.38 million vehicles in the quarter, compared with 2...Reuters
Mon, Jan 12
Clene Announces Additional Cnm-Au8 Biomarker Data Supporting Potential NDA Filing For Upcoming In-Person FDA Meeting
Jan 12 (Reuters) - Clene Inc CLNN.O:CLENE ANNOUNCES ADDITIONAL CNM-AU8 BIOMARKER DATA SUPPORTING POTENTIAL NDA FILING FOR UPCOMING IN-PERSON FDA MEETINGCLENE INC - FDA GRANTS IN-PERSON TYPE C MEETING FOR CNM-AU8 POTENTIAL NDA FILING IN Q1 2026Reuters
Mon, Jan 12
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Jan 12 (Reuters) - CK Life Sciences Intl (Holdings) Inc 0775.HK:DOGWOOD THERAPEUTICS, INC. ANNOUNCES FINANCING OF UP TO $26.8 MILLION TO PROGRESS HALNEURON® THROUGH PHASE 2B DEVELOPMENTReuters
Mon, Jan 12
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum
Jan 12 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACEUTICALS ANNOUNCES PRELIMINARY UNAUDITED 2025 RESULTS, DEMONSTRATING STRONG COMMERCIAL GROWTH AND PIPELINE MOMENTUMMIRUM PHARMACEUTICALS INC - PRELIM 2025 NET PRODUCT SALES OF APPROXIMATELY $520 MILLION EXCEED UPPER END OF GUIDANCEMIRU...Reuters
Mon, Jan 12
Lysander Funds Announces Listing Of ETF Series Of Lysander-Canso U.S. Corporate Value Bond Fund
Jan 12 (Reuters) - Lysander Canso U S Corporate Value Bond Fund Units ETF LYUVu.TO:LYSANDER FUNDS ANNOUNCES LISTING OF ETF SERIES OF LYSANDER-CANSO U.S. CORPORATE VALUE BOND FUNDFurther company coverage: [LYUVu.TO]Reuters
Mon, Jan 12
Ptc Therapeutics Provides Update At J.P. Morgan Annual Healthcare Conference
Jan 12 (Reuters) - PTC Therapeutics Inc PTCT.O:PTC THERAPEUTICS PROVIDES UPDATE AT J.P. MORGAN ANNUAL HEALTHCARE CONFERENCEPTC THERAPEUTICS INC - 2026 PRODUCT REVENUE GUIDANCE OF $700 – 800MPTC THERAPEUTICS INC - UNAUDITED 2025 TOTAL PRODUCT AND ROYALTY REVENUE OF APPROXIMATELY $823M, EXCEEDING GUID...Reuters
Mon, Jan 12
